Latest News - Business

June 23, 2010 | Globes Online

On June 23, Gamida Cell announced that its joint venture with Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) received fast track designation from the U.S. Food and Drug Administration (FDA) for its stem cell treatment for cancers of the blood.
Their product, StemEx, is in development as an alternative to bone marrow transplants for patients suffering from leukemia and lymphoma.

May 20, 2010 | The Street

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell technologies, announced that BrainStorm’s Chief Technology Advisor, Dr. Avinoam Kadouri, was invited to act as a Chairman at the World Stem Cells and Regenerative Medicine Congress being held in London, England.

May 13, 2010 | Bloomberg Business Week

An Australian developer of stem-cell therapies, Mesoblast Ltd., plans to introduce its first product by 2012. This announcement comes after Mesoblast agreed to buy all the shares of Angioblast Systems Inc. that it doesn’t already own.
Mesoblast will acquire the remaining 67 percent of Angioblast, Mesoblast said in a statement on May 12. Mesoblast also raised $37 million Australian ($33 million US) by selling shares to investors. The company will use these funds to finance patient studies, Chief Executive Officer Silviu Itescu reported.

May 2, 2010 | Business Standard

Cipla, India’s largest domestic drug manufacturer, has joined forces with the Manipal Group-promoted Stempeutics Research in order to market stem cell based treatments.

Cipla will fund clinical trials and further develop two products in development by Stempeutics. In return for further investment to develop more products, Cipla will get marketing rights on a transfer-pricing basis during commercialization.

April 19, 2010 | San Diego Business Journal

Pfizer Inc. stated that it would start selling reagents for use in stem cell research through Stemgent Inc., a biotech company with operations in San Diego and Boston.
Under the terms of their agreement, Stemgent will sell fully licensed compounds as off-the-shelf products for use in stem cell research. The financial terms of the contract were not revealed.
Pfizer said the collaboration might serve to benefit researchers who are testing a range of stem cell and cell-based applications, including cancer, neuroscience, and metabolic disease.

April 11, 2010 | Xconomy

Fate Therapeutics’ “empire” already extends from coast to coast. Now it is expanding northward into Canada. The San Diego-based developer of stem cell technologies has agreed to acquire Ottawa-based Verio Therapeutics, which will add more bright minds and clever techniques to develop drugs that spark the human body to regenerate damaged tissue.

March 4, 2010 | Genetic Engineering and Biotechnology News

Lonza has negotiated exclusive, global rights to distribute Cor.At® mouse embryonic stem cell-derived cardiomyocytes produced by Axiogenesis. Lonza states that the deal signals its entrance into the pluripotent stem cell market. The company plans to begin offering additional differentiated cell types in 2010.

March 1, 2010 | CNN Money

Vivakor, Inc. (OTCBB:VIVK) announced that it has developed a new way of cryopreservation for human stem cells. This new method takes advantage of the superior thermal conductivity of Vivakor's own VivaThermic vials and reduces overall cryopreservation and thawing recovery times. A select number of leading stem cell researchers and institutions have started testing Vivakor’s new method.

February 10, 2010 | Business Week

A Massachusetts Institute of Technology (MIT) scientist, Rudolf Jaenisch, is set to be granted a U.S. patent for finding a way to turn cells taken from mammals’ bodies into stem cells. This discovery had also been claimed by two other scientists.

February 2, 2010 | CNN

Up and coming IR Biosciences' ImmuneRegen (OTCBB: IRBS) has been garnering more attention than similar biotech companies from such places as the National Institute of Health, the National Cancer Institute, Biomedical Advanced Research and Development Authority, and the American armed forces.

For Stem Cell treatment inquire now